BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion ...
FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx and ...
The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...
Foundation Medicine remains one of the chief contributors to ComboMATCH, the largest of its kind initiative to test effectiveness of biomarker-targeted cancer treatment combinations BOSTON--(BUSINESS ...
The FDA approved Foundation Medicine’s cancer gene test Thursday. CMS also proposed national coverage of the test for Medicare beneficiaries with advanced cancer. The FoundationOne CDx is an in vitro ...
First and only company with 100 approved and active companion diagnostic indications for next-generation sequencing in the United States and Japan, setting the standard for high-quality genomic ...
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation ...
Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced that the company and its research collaborators will present 11 abstracts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results